Disclosures for "NeuroPathways: A Novel, Population-Specific Information and Support Intervention for Patients with Newly Diagnosed Primary Malignant Brain Tumors")
-
Ms. Strander has nothing to disclose.
-
Miss Podgurski has nothing to disclose.
-
Miss Psenka has nothing to disclose.
-
Dr. Traeger has nothing to disclose.
-
The institution of Jennifer Temel has received research support from Blue Note Therapeutics.
-
Dr. Forst has received stock or an ownership interest from Eli Lilly. Dr. Forst has received research support from Conquer Cancer Foundation of the American Society of Clinical Oncology. Dr. Forst has received research support from Palliative Care Research Cooperative Group. Dr. Forst has received research support from American Cancer Society Institutional Research Grant.